MX2021008207A - Proteínas de fusión multifuncionales y usos de las mismas. - Google Patents
Proteínas de fusión multifuncionales y usos de las mismas.Info
- Publication number
- MX2021008207A MX2021008207A MX2021008207A MX2021008207A MX2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A MX 2021008207 A MX2021008207 A MX 2021008207A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- functional fusion
- fusion protein
- functional
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789212P | 2019-01-07 | 2019-01-07 | |
| PCT/US2020/012624 WO2020146423A1 (en) | 2019-01-07 | 2020-01-07 | Multi-functional fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008207A true MX2021008207A (es) | 2021-11-04 |
Family
ID=71521906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008207A MX2021008207A (es) | 2019-01-07 | 2020-01-07 | Proteínas de fusión multifuncionales y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12497439B2 (enExample) |
| EP (1) | EP3908664A4 (enExample) |
| JP (1) | JP7587505B2 (enExample) |
| KR (2) | KR20260116815A (enExample) |
| CN (1) | CN113518823B (enExample) |
| AU (2) | AU2020207265B2 (enExample) |
| BR (1) | BR112021013415A2 (enExample) |
| CA (1) | CA3125748A1 (enExample) |
| IL (1) | IL284679A (enExample) |
| MX (1) | MX2021008207A (enExample) |
| SG (1) | SG11202107454UA (enExample) |
| WO (1) | WO2020146423A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| CN113518823B (zh) | 2019-01-07 | 2025-05-02 | 托马斯杰斐逊大学 | 多功能的融合蛋白及其用途 |
| EP4175656A4 (en) * | 2020-07-03 | 2024-10-16 | The Trustees of Columbia University in the City of New York | POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| WO2022188129A1 (zh) * | 2021-03-12 | 2022-09-15 | 利时雨 | 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用 |
| CN118369336A (zh) * | 2022-04-15 | 2024-07-19 | Im生技股份有限公司 | 具有改进半衰期的融合蛋白平台 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056591A1 (en) | 2000-02-03 | 2001-08-09 | Thomas Jefferson University | vMIP-II PEPTIDE ANTAGONISTS OF CXCR4 |
| US7897152B2 (en) * | 2000-09-18 | 2011-03-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Viral chemokine-antigen fusion proteins |
| US8021658B2 (en) * | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| DE102009047243A1 (de) | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| EP2950814A4 (en) | 2013-01-31 | 2016-06-08 | Univ Jefferson | FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CN109608544B (zh) * | 2015-11-17 | 2022-09-16 | 苏州盛迪亚生物医药有限公司 | Pd-l1抗体、其抗原结合片段及其医药用途 |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| JP6732915B2 (ja) * | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| WO2018209017A1 (en) * | 2017-05-10 | 2018-11-15 | The General Hospital Corporation | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor |
| RU2766590C2 (ru) * | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| CN113518823B (zh) | 2019-01-07 | 2025-05-02 | 托马斯杰斐逊大学 | 多功能的融合蛋白及其用途 |
-
2020
- 2020-01-07 CN CN202080016520.5A patent/CN113518823B/zh active Active
- 2020-01-07 AU AU2020207265A patent/AU2020207265B2/en active Active
- 2020-01-07 BR BR112021013415A patent/BR112021013415A2/pt unknown
- 2020-01-07 WO PCT/US2020/012624 patent/WO2020146423A1/en not_active Ceased
- 2020-01-07 JP JP2021539880A patent/JP7587505B2/ja active Active
- 2020-01-07 MX MX2021008207A patent/MX2021008207A/es unknown
- 2020-01-07 KR KR1020267024064A patent/KR20260116815A/ko active Pending
- 2020-01-07 US US17/421,053 patent/US12497439B2/en active Active
- 2020-01-07 EP EP20738361.3A patent/EP3908664A4/en active Pending
- 2020-01-07 SG SG11202107454UA patent/SG11202107454UA/en unknown
- 2020-01-07 KR KR1020217024898A patent/KR102996287B1/ko active Active
- 2020-01-07 CA CA3125748A patent/CA3125748A1/en active Pending
-
2021
- 2021-07-07 IL IL284679A patent/IL284679A/en unknown
-
2025
- 2025-11-04 US US19/378,976 patent/US20260193312A1/en active Pending
-
2026
- 2026-06-23 AU AU2026204884A patent/AU2026204884A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020207265B2 (en) | 2026-03-26 |
| CN113518823A (zh) | 2021-10-19 |
| JP2022528030A (ja) | 2022-06-08 |
| CA3125748A1 (en) | 2020-07-16 |
| EP3908664A4 (en) | 2023-01-25 |
| US20220056102A1 (en) | 2022-02-24 |
| BR112021013415A2 (pt) | 2021-12-28 |
| JP7587505B2 (ja) | 2024-11-20 |
| KR20220025698A (ko) | 2022-03-03 |
| EP3908664A1 (en) | 2021-11-17 |
| AU2026204884A1 (en) | 2026-07-09 |
| US20260193312A1 (en) | 2026-07-09 |
| SG11202107454UA (en) | 2021-08-30 |
| KR20260116815A (ko) | 2026-07-28 |
| IL284679A (en) | 2021-08-31 |
| KR102996287B1 (ko) | 2026-07-24 |
| CN113518823B (zh) | 2025-05-02 |
| WO2020146423A1 (en) | 2020-07-16 |
| AU2020207265A1 (en) | 2021-08-12 |
| US12497439B2 (en) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| PH12020500648A1 (en) | Il-15 variants and uses thereof | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| EP4623992A3 (en) | Antibodies specifically binding to human il-1r7 | |
| BR112021013415A2 (pt) | Proteínas de fusão multifuncionais e usos das mesmas | |
| MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| MX2019010397A (es) | Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina. | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| PH12015502063A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| MX2022004577A (es) | Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune. | |
| PH12018500098A1 (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
| MX2018014716A (es) | Anticuerpos anti-tnfrsf25. | |
| ZA202104287B (en) | Novel fusion proteins specific for cd137 and gpc3 | |
| PH12021551494A1 (en) | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| MX2019006444A (es) | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. |